The National Institute for Health and Care Excellence (NICE) has released its final draft guidance recommending Itulazax® (Betula verrucosa)—the first sublingual (under the tongue) tablet immunotherapy, which could help up to 27,000…
Read more
The UK medicines regulator (MHRA) has approved EURneffy®, the country’s first needle-free adrenaline nasal spray for the emergency treatment of serious allergic reactions (anaphylaxis) in adults and children weighing 30kg or more….
Read more
Anaphylm is a medicine being developed by Aquestive Therapeutics for the emergency treatment of serious allergic reactions, including anaphylaxis.
Read more
Researchers at the University of Southampton are inviting parents and caregivers of young infants to take part in a research study to help prevent food allergy in babies. This research is part…
Read more
A new study using data from the European Anaphylaxis Registry has identified important changes in which tree nuts are most likely to cause serious allergic reactions (anaphylaxis) in children and adults across…
Read more
A new study, led by King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, has shown promising results, demonstrating that peanut oral immunotherapy (OIT) may be an effective treatment for…
Read more
Researchers at the University of Bristol and the James Lind Alliance invite you to take part in the second phase of a UK-wide survey to prioritise the most urgent unanswered questions about childhood food…
Read more
Last week Anaphylaxis UK celebrated National Weaning Week 2025—a time dedicated to supporting families as they introduce solid foods to their babies. We marked the occasion by publishing a podcast, offering practical,…
Read more
We are delighted to announce that Anaphylaxis UK has been successful in its application to Innovate UK for funding to set up a Knowledge Transfer Partnership (KTP) with the University of Surrey to offer support that addresses the psychological impact of living with serious allergies.
Read more